By investigating the impact of vitexin on the STAT3 signaling pathway and key cancer markers, researchers have demonstrated that vitexin can successfully disrupt the sustained activation of JAK1, JAK2, and STAT3 in hepatocellular carcinoma (HCC) cells. Here, JAK1 is linked to hepatocellular carcinoma.